Loading
A phase 1 trial of DNX-2440 run by Clinica Universidad de Navarra, Universidad de Navarra, terminated.
DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma is a phase 1 interventional study registered as NCT03714334 by Clinica Universidad de Navarra, Universidad de Navarra, with 16 participants enrolled, started 2018-10-16. Conditions recorded: Glioblastoma and Glioblastoma, Adult. Interventions recorded: DNX-2440 injection.
Shares DNAtrix, Glioma & glioblastoma and the tag pipeline.
Shares DNAtrix, Glioma & glioblastoma and the tag pipeline.
Shares DNAtrix, Glioma & glioblastoma and the tag pipeline.
Shares DNAtrix, Glioma & glioblastoma and the tag pipeline.
Shares DNAtrix and the tag pipeline.
Shares DNAtrix and the tag pipeline.
Shares DNAtrix and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/